Opinion/decision on a Paediatric investigation plan (PIP): Fetcroja,Cefiderocol, decision type: , therapeutic area: , PIP number: P/0441/2022

Opinion/decision on a Paediatric investigation plan (PIP): Insulin human (NTRA-2112), decision type: , therapeutic area: , PIP number: P/0458/2022

Opinion/decision on a Paediatric investigation plan (PIP): Voxzogo,Vosoritide, decision type: , therapeutic area: , PIP number: P/0453/2022

Human medicines European public assessment report (EPAR): Ziagen, abacavir, HIV Infections, Date of authorisation: 08/07/1999, Revision: 47, Status: Authorised

Appendix 1: Acceptable intakes established for N-nitrosamines

Opinion/decision on a Paediatric investigation plan (PIP): Finasteride,tadalafil, decision type: , therapeutic area: , PIP number: P/0461/2022

Opinion/decision on a Paediatric investigation plan (PIP): Rosuvastatin (calcium),Telmisartan, decision type: , therapeutic area: , PIP number: P/0460/2022

Opinion/decision on a Paediatric investigation plan (PIP): Derivative of (3S,3'S,3a'S,10a'S)-3'-phenyl-3',3a',10',10a'-tetrahydro-1'H-spiro[indoline-3,2'- pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazol]-2-one, decision type: , therapeutic area: , PIP number: P/0459/2022

Responses to list of issues - GFR slope as a Surrogate Endpoint in RCT for CKD

EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep